H-2 Typing of MRL/lpr Mice Transplanted With BMCs Containing Various Percentages of T Cells
| % of T Cells Added* . | Survival Rate . | No. of Mice Bearing-151 Donor Phenotype (H-2Kb) . | No. of Mice Bearing Recipient Phenotype (H-2Kk) . |
|---|---|---|---|
| 0.05 | 4/5-152 | 0 | 4 |
| 0.1 | 3/5 | 0 | 3 |
| 0.5 | 4/5 | 3 | 1 |
| 1.0 | 5/5 | 5 | 0 |
| % of T Cells Added* . | Survival Rate . | No. of Mice Bearing-151 Donor Phenotype (H-2Kb) . | No. of Mice Bearing Recipient Phenotype (H-2Kk) . |
|---|---|---|---|
| 0.05 | 4/5-152 | 0 | 4 |
| 0.1 | 3/5 | 0 | 3 |
| 0.5 | 4/5 | 3 | 1 |
| 1.0 | 5/5 | 5 | 0 |
*T cells from the peripheral blood of donor mice were added to 5 × 107 T cell-depleted BMCs, and injected into recipients that had been treated with CY/2X/Bone.
Peripheral blood mononuclear cells were collected 6 weeks after treatment, and stained with FITC-labeled anti-H-2Kk and PE-labeled anti-H-2Kb to detect donor- and recipient-derived cells, respectively.
Numbers represent live/total recipients 6 weeks after the treatment.